RNS Number : 3753A
NetScientific PLC
07 June 2016


NetScientific plc

("NetScientific" or the "Company" or the "Group")

NetScientific Portfolio PDS Biotechnology presents at BIO 2016

NetScientific makes further investment in PDS Biotechnology

London, UK - 7 June 2016 - NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased to note that its therapeutics portfolio company, PDS Biotechnology, will today be presenting at BIO 2016 in San Francisco, California. Frank Bedu-Addo, CEO of PDS Biotechnology, will discuss the recently announced positive results for the Phase I human clinical trial as well as PDS's plans for upcoming Phase 2 clinical trials in several HPV-related cancers, including cervical cancer, head and neck cancers and intra-epithelial neoplasias as well as prostate, ovarian, breast and colorectal cancer.

In addition, further to the Company's announcement of 13 April 2016, NetScientific can confirm that it has invested a further $500,000 in PDS Biotechnology. This investment has been made by way of a convertible loan, and the funding will be used to assist in the implementation of its Phase 2 programmes.

Commenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: "The promising results from PDS's Phase II results have provided positive validation of the Versamune® T-cell activating platform technology. We now look forward to continuing our support of this exciting portfolio company as is looks to further corroborate the potential of PDS0101 in Phase II development."

The full text of the announcement from PDS Biotechnology can be found below.

For more information, please contact:


François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO


Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton


Tel: +44 (0)20 3709 5700



About NetScientific

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

PDS Biotechnology

CEO Frank Bedu-Addo Presenting at BIO 2016

07 June 2016 - PDS Biotechnology, a private clinical stage immuno-oncology company developing novel immunotherapies, announces that CEO Frank Bedu-Addo will make a presentation at BIO 2016, being held at the Moscone Center, 747 Howard Street, San Francisco, California from June 6-9 2016.

The presentation will be held in Theater 1 on Tuesday, June 7, commencing at 2:15pm, and provide information on the positive safety and CD8 + T-cell induction results from the PDS0101 Phase 1 human clinical trial.  PDS0101 is the company's lead program based on its proprietary Versamune® T-cell activating platform.  Dr. Bedu-Addo will discuss the unique combination of human safety and T-cell potency and its impact on enhancing the development of effective immunotherapies for cancer.  The talk will also cover PDS' plans for upcoming Phase 2 clinical trials in several HPV-related cancers, as well as other cancers including prostate, ovarian, breast and colorectal cancers.  

The BIO convention brings together over 15,000 biotechnology and pharma leaders, covering a wide spectrum of life sciences areas including drug discovery, bio-manufacturing, genomics and more.

About the Versamune® T-Cell Activating Platform: 

Versamune® is a synthetic T-cell activating nanotechnology that overcomes a key obstacle facing cancer immunotherapy by facilitating efficient access of cancer protein antigens to pathways that enable their effective presentation to killer T-cells.  This process trains the body's T-cells to recognize and efficiently attack the cancer.  The ingredient of the Versamune® platform has also been proven to activate critical immunological signaling pathways that result in the safe production of immunological proteins known as cytokines and chemokines locally within the lymph nodes to recruit T-cells, and enhance T-cell proliferation as well as the killing activity of T-cells.  Activation of these immunological pathways may also be responsible for the ability of the Versamune® -based immunotherapies to reduce the population of immune suppressive cells and to facilitate the killing activity of the T-cells specifically within the tumors.

About PDS Biotechnology:

PDS Biotech is a clinical stage immuno-oncology company committed to the development of simpler, safer and more effective immunotherapies.  An example of the company's approach is the Versamune® T-cell activating platform, the first immuno-oncology technology to successfully combine the three critical attributes of effective immunotherapies in a simple nanoparticle, while also eliminating the potentially debilitating toxicities of some of the leading immunotherapy approaches.  PDS Biotechnology's oncology pipeline includes products for prostate, ovarian, breast and colorectal cancers, in addition to its lead PDS0101 program for several HPV-related cancers.

 Contact Details

PDS Biotechnology Corp.

Frank Bedu-Addo, Ph.D., CEO       

Michael King, M.B.A., CFO

Phone: +1-732-640-0145

Email:  Execinfo@pdsbiotech.com




This information is provided by RNS
The company news service from the London Stock Exchange